Treatment study for advanced cervical cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a new drug combination for people with advanced cervical cancer that has spread or returned after platinum-based chemotherapy. The goal is to see if this treatment can shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have cervical cancer that has spread or returned and is not curable with surgery or radiation.
- You have already had chemotherapy with a platinum drug, and the cancer continued to grow or came back.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are expected to live at least 3 more months.
- You do not have other types of cancer, active autoimmune disease, or serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs together for people with cervical cancer that has returned or spread. The goal is to see if the combination can shrink tumors or slow the disease better than current options.
This trial tests a new drug called QL706 combined with chemotherapy, with or without another drug called bevacizumab, for people with cervical cancer that has returned or spread and no longer responds to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests two immune-boosting drugs (iparomlimab and tuvonralimab) combined with standard chemotherapy given before surgery for locally advanced cervical cancer. The goal is to shrink the cancer and improve survival chances.
This trial tests whether adding two immunotherapy drugs (iparomlimab and tuvonralimab) to standard chemoradiation can help people with cervical cancer that has returned or spread to a few new places. The goal is to see if this combination improves outcomes for those whose cancer is no longer responding to initial treatment.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy before surgery for cervical cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes, and it is given as a neoadjuvant (before-surgery) approach.
This study tests a new combination of two drugs for cervical cancer that has returned or spread and did not get better with platinum-based chemotherapy. It aims to see if the combination works better than the standard treatment options.
Hear when a new Recurrent or Metastatic Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.